Growth hormone for IVF, in women 40 and over
Move through the ages and see what the trials actually show about adding growth hormone (HGH) in IVF.
Growth hormone for IVF, in women 40 and over
Growth hormone (GH, or HGH) is sometimes added to the normal IVF stimulation drugs, usually for older women or poor responders. Any single trial has been small, so the useful evidence is a 2023 meta-analysis that pooled them and, importantly, isolated women aged 40 and over. Here is what it found, why the size looks big, and the honest caveat. A companion study on embryo euploidy is shown too, and every figure is labelled with its source.
Adding GH, in women 40 and over
2023 meta-analysisThese are odds ratios, a relative measure. An odds ratio of 2 means about twice the odds, not twice the rate. On a low older-women baseline, that is still a large lift.
Embryo euploidy in advanced maternal age
companion studyA separate study in older women found GH was linked to a higher share of chromosomally normal (euploid) blastocysts, the plausible reason for the live-birth lift above.
What the trials actually used
across the trialsIU means International Units, a measure of biological activity. For growth hormone, roughly 3 IU is about 1 milligram. Doses varied a lot; here are the two patterns to raise with a clinic.
The honest caveat
The individual trials are small, some with very few events, and most of the original papers sit behind paywalls, so the pooled numbers come from the meta-analysis's own extracted data. Odds ratios also overstate the effect versus plain rate differences on a low baseline. This is a large, promising, older-women-specific signal that deserves a real conversation with a clinic, not a proven protocol.